Isthmus Partners LLC Buys 2,280 Shares of Johnson & Johnson (NYSE:JNJ)

Isthmus Partners LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 99,775 shares of the company’s stock after purchasing an additional 2,280 shares during the period. Johnson & Johnson makes up about 1.8% of Isthmus Partners LLC’s investment portfolio, making the stock its 17th largest holding. Isthmus Partners LLC’s holdings in Johnson & Johnson were worth $14,429,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. State Street Corp boosted its holdings in shares of Johnson & Johnson by 0.9% during the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company’s stock valued at $21,755,874,000 after purchasing an additional 1,154,088 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company’s stock valued at $9,064,149,000 after acquiring an additional 1,004,763 shares during the last quarter. FMR LLC increased its stake in Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company’s stock worth $2,968,440,000 after acquiring an additional 1,265,748 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company’s stock valued at $2,630,216,000 after purchasing an additional 547,714 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after purchasing an additional 1,729,281 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Barclays upped their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Finally, Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Trading Up 0.6 %

NYSE JNJ opened at $166.81 on Monday. The company has a fifty day moving average of $152.95 and a 200 day moving average of $156.24. The company has a market capitalization of $401.61 billion, a PE ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.